Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · IEX Real-Time Price · USD
3.860
+0.310 (8.73%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Summit Therapeutics Employees
Summit Therapeutics had 105 employees on December 31, 2023. The number of employees increased by 28 or 36.36% compared to the previous year.
Employees
105
Change (1Y)
28
Growth (1Y)
36.36%
Revenue / Employee
n/a
Profits / Employee
-$5,856,457
Market Cap
2.71B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 105 | 28 | 36.36% |
Dec 31, 2022 | 77 | -33 | -30.00% |
Dec 31, 2021 | 110 | 29 | 35.80% |
Dec 31, 2020 | 81 | 11 | 15.71% |
Dec 31, 2019 | 70 | 9 | 14.75% |
Dec 31, 2018 | 61 | -15 | -19.74% |
Dec 31, 2017 | 76 | 36 | 90.00% |
Dec 31, 2016 | 40 | 3 | 8.11% |
Dec 31, 2015 | 37 | 14 | 60.87% |
Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Premier | 2,800 |
Certara | 1,391 |
Indivior | 1,164 |
Merus | 229 |
Rhythm Pharmaceuticals | 226 |
Celldex Therapeutics | 160 |
CG Oncology | 61 |
MoonLake Immunotherapeutics | 50 |
SMMT News
- 2 days ago - Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 - Business Wire
- 15 days ago - Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors - Business Wire
- 17 days ago - Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum - Business Wire
- 17 days ago - Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor - Reuters
- 17 days ago - Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer - PRNewsWire
- 5 weeks ago - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 - Business Wire
- 6 weeks ago - Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 - Business Wire
- 6 weeks ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT - PRNewsWire